Impact	O
of	O
idiopathic	B-DS
pulmonary	I-DS
fibrosis	I-DS
on	O
advanced	O
non	B-DS
-	I-DS
small	I-DS
cell	I-DS
lung	I-DS
cancer	I-DS
survival	O

Purpose	O

The	O
clinical	O
features	O
of	O
patients	O
with	O
advanced	O
non	B-DS
-	I-DS
small	I-DS
cell	I-DS
lung	I-DS
cancer	I-DS
(	O
NSCLC	B-DS
)	O
and	O
interstitial	B-DS
lung	I-DS
disease	I-DS
(	O
ILD	B-DS
)	O
have	O
not	O
fully	O
been	O
elucidated	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
clinical	O
features	O
of	O
these	O
patients	O
,	O
particularly	O
with	O
idiopathic	B-DS
pulmonary	I-DS
fibrosis	I-DS
(	O
IPF	B-DS
).	O

Methods	O

Data	O
on	O
218	O
patients	O
with	O
pathologically	O
confirmed	O
diagnoses	O
of	O
NSCLC	B-DS
who	O
had	O
been	O
treated	O
with	O
chemotherapy	O
and	O
/	O
or	O
molecular	O
targeted	O
therapy	O
were	O
retrospectively	O
analyzed	O
for	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
),	O
overall	O
survival	O
(	O
OS	O
),	O
responses	O
to	O
first	O
-	O
line	O
therapy	O
,	O
and	O
incidence	O
of	O
acute	O
exacerbations	O
(	O
AEs	O
).	O

Results	O

Fifty	O
-	O
three	O
of	O
the	O
218	O
patients	O
were	O
diagnosed	O
with	O
ILD	B-DS
,	O
and	O
34	O
of	O
them	O
with	O
IPF	B-DS
.	O

The	O
frequency	O
of	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
(	O
EGFR	B-GP
)	O
mutation	O
was	O
significantly	O
lower	O
in	O
ILD	B-DS
and	O
IPF	B-DS
patients	O
than	O
in	O
non	O
-	O
ILD	B-DS
patients	O
(	O
2	O
or	O
0	O
vs	O
.	O
32	O
%,	O
respectively	O
).	O

Median	O
PFS	O
and	O
OS	O
were	O
significantly	O
shorter	O
in	O
both	O
ILD	B-DS
and	O
IPF	B-DS
patients	O
than	O
in	O
non	O
-	O
ILD	B-DS
patients	O
(	O
118	O
,	O
92	O
,	O
and	O
196	O
days	O
for	O
PFS	O
,	O
and	O
267	O
,	O
223	O
,	O
and	O
539	O
days	O
for	O
OS	O
,	O
respectively	O
).	O

Multivariate	O
analysis	O
showed	O
that	O
poor	O
performance	O
status	O
,	O
absence	O
of	O
EGFR	B-GP
mutation	O
,	O
and	O
presence	O
of	O
IPF	B-DS
were	O
poor	O
prognostic	O
factors	O
for	O
PFS	O
and	O
OS	O
.	O

Disease	O
control	O
rate	O
(	O
DCR	O
)	O
was	O
significantly	O
lower	O
in	O
ILD	B-DS
and	O
IPF	B-DS
patients	O
than	O
in	O
non	O
-	O
ILD	B-DS
patients	O
regardless	O
of	O
the	O
presence	O
of	O
EGFR	B-GP
mutation	O
(	O
67	O
or	O
53	O
vs	O
.	O
85	O
%,	O
respectively	O
).	O

The	O
incidence	O
of	O
AEs	O
of	O
ILD	B-DS
was	O
significantly	O
higher	O
during	O
chemotherapy	O
with	O
docetaxel	O
-	O
containing	O
regimens	O
(	O
seven	O
of	O
38	O
;	O
18	O
.	O
4	O
%).	O

Conclusions	O

Both	O
IPF	B-DS
and	O
ILD	B-DS
were	O
associated	O
with	O
lower	O
EGFR	B-GP
positivity	O
,	O
lower	O
DCR	O
,	O
and	O
shorter	O
PFS	O
and	O
OS	O
in	O
advanced	O
NSCLC	B-DS
patients	O
.	O

Introduction	O

Interstitial	B-DS
lung	I-DS
diseases	I-DS
(	O
ILDs	B-DS
),	O
also	O
called	O
interstitial	B-DS
lung	I-DS
abnormalities	I-DS
(	O
ILA	B-DS
)	O
or	O
interstitial	B-DS
pneumonia	I-DS
(	O
IP	B-DS
),	O
are	O
characterized	O
by	O
diffuse	B-DS
pulmonary	I-DS
interstitial	I-DS
abnormalities	I-DS
that	O
often	O
lead	O
to	O
fibrosis	O
(	O
Borchers	O
et	O
al	O
.	O
2011	O
).	O

Recent	O
evidence	O
has	O
shown	O
that	O
preexisting	O
ILD	B-DS
is	O
associated	O
with	O
shorter	O
survival	O
in	O
patients	O
with	O
advanced	O
non	B-DS
-	I-DS
small	I-DS
cell	I-DS
lung	I-DS
cancer	I-DS
(	O
NSCLC	B-DS
)	O
(	O
Kinoshita	O
et	O
al	O
.	O
2012	O
;	O
Nishino	O
et	O
al	O
.	O
2015	O
).	O

In	O
a	O
study	O
of	O
NSCLC	B-DS
patients	O
receiving	O
chemotherapy	O
,	O
22	O
of	O
whom	O
had	O
idiopathic	B-DS
interstitial	I-DS
pneumonia	I-DS
(	O
IIP	B-DS
),	O
IIP	B-DS
was	O
found	O
to	O
be	O
a	O
significantly	O
unfavorable	O
factor	O
for	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
(	O
95	O
.	O
0	O
vs	O
.	O
199	O
.	O
5	O
days	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
(	O
163	O
.	O
0	O
vs	O
.	O
400	O
.	O
0	O
days	O
)	O
(	O
Kinoshita	O
et	O
al	O
.	O
2012	O
).	O

In	O
another	O
study	O
,	O
NSCLC	B-DS
patients	O
with	O
high	O
ILA	B-DS
scores	O
according	O
to	O
computed	O
tomography	O
(	O
CT	O
)	O
findings	O
had	O
shorter	O
OS	O
(	O
n	O
=	O
17	O
,	O
7	O
.	O
2	O
months	O
)	O
than	O
those	O
without	O
ILA	B-DS
(	O
n	O
=	O
103	O
,	O
14	O
.	O
8	O
months	O
)	O
(	O
Nishino	O
et	O
al	O
.	O
2015	O
).	O

Idiopathic	B-DS
pulmonary	I-DS
fibrosis	I-DS
(	O
IPF	B-DS
),	O
the	O
commonest	O
type	O
of	O
ILD	B-DS
(	O
Borchers	O
et	O
al	O
.	O
2011	O
),	O
is	O
defined	O
as	O
a	O
specific	O
form	O
of	O
chronic	O
,	O
progressive	O
fibrosing	O
IP	B-DS
of	O
unknown	O
cause	O
,	O
occurring	O
primarily	O
in	O
older	O
adults	O
,	O
limited	O
to	O
the	O
lungs	O
,	O
and	O
associated	O
with	O
the	O
histopathologic	O
and	O
/	O
or	O
radiologic	O
patterns	O
of	O
usual	B-DS
interstitial	I-DS
pneumonia	I-DS
(	O
UIP	B-DS
)	O
(	O
Raghu	O
et	O
al	O
.	O
2011	O
).	O

IPF	B-DS
was	O
recently	O
reported	O
to	O
be	O
a	O
poor	O
prognostic	O
factor	O
in	O
patients	O
with	O
surgically	O
treated	O
NSCLC	B-DS
(	O
Goto	O
et	O
al	O
.	O
2014	O
;	O
Lee	O
et	O
al	O
.	O
2014	O
).	O

Only	O
one	O
study	O
has	O
focused	O
on	O
the	O
efficacy	O
of	O
chemotherapy	O
in	O
advanced	O
NSCLC	B-DS
with	O
IPF	B-DS
(	O
Watanabe	O
et	O
al	O
.	O
2013	O
).	O

The	O
authors	O
reported	O
that	O
21	O
patients	O
with	O
IPF	B-DS
had	O
an	O
overall	O
response	O
rate	O
(	O
RR	O
),	O
PFS	O
,	O
and	O
OS	O
of	O
42	O
.	O
9	O
%,	O
5	O
.	O
4	O
,	O
and	O
11	O
.	O
4	O
months	O
,	O
respectively	O
(	O
Watanabe	O
et	O
al	O
.	O
2013	O
).	O

No	O
published	O
studies	O
have	O
compared	O
the	O
survival	O
of	O
IPF	B-DS
and	O
non	O
-	O
ILD	B-DS
patients	O
with	O
advanced	O
NSCLC	B-DS
.	O

Because	O
there	O
is	O
limited	O
clinical	O
information	O
regarding	O
advanced	O
NSCLC	B-DS
patients	O
with	O
IPF	B-DS
,	O
we	O
retrospectively	O
compared	O
the	O
efficacy	O
of	O
chemotherapy	O
and	O
survival	O
in	O
NSCLC	B-DS
patients	O
with	O
ILD	B-DS
or	O
IPF	B-DS
with	O
that	O
in	O
patients	O
without	O
ILD	B-DS
.	O

In	O
addition	O
,	O
we	O
investigated	O
the	O
incidence	O
,	O
risk	O
factors	O
,	O
and	O
outcome	O
of	O
acute	O
exacerbations	O
(	O
AEs	O
)	O
after	O
receiving	O
chemotherapy	O
.	O

Materials	O
and	O
methods	O

Patients	O

This	O
study	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
Kagawa	O
University	O
.	O

Patients	O
with	O
pathologically	O
confirmed	O
advanced	O
(	O
stage	O
IIIB	O
or	O
IV	O
)	O
NSCLC	B-DS
who	O
presented	O
to	O
the	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Kagawa	O
University	O
Hospital	O
,	O
between	O
January	O
2007	O
and	O
July	O
2015	O
were	O
retrospectively	O
identified	O
,	O
and	O
relevant	O
clinical	O
and	O
laboratory	O
data	O
were	O
collected	O
from	O
their	O
medical	O
records	O
.	O

Patients	O
who	O
(	O
1	O
)	O
had	O
received	O
definitive	O
thoracic	O
irradiation	O
(	O
usually	O
more	O
than	O
60	O
Gy	O
),	O
(	O
2	O
)	O
had	O
another	O
concomitant	O
active	O
malignancy	B-DS
,	O
or	O
(	O
3	O
)	O
had	O
received	O
only	O
best	O
supportive	O
care	O
were	O
excluded	O
,	O
whereas	O
those	O
treated	O
with	O
chemotherapy	O
and	O
/	O
or	O
molecular	O
targeted	O
therapy	O
such	O
as	O
tyrosine	B-GP
kinase	I-GP
inhibitors	O
(	O
TKIs	O
)	O
for	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
(	O
EGFR	B-GP
)	O
were	O
included	O
.	O

Classification	O
of	O
ILD	B-DS
and	O
diagnosis	O
of	O
IPF	B-DS
and	O
AE	O

The	O
classification	O
of	O
ILD	B-DS
was	O
made	O
in	O
accordance	O
with	O
the	O
ATS	O
/	O
ERS	O
/	O
Japanese	O
Respiratory	O
Society	O
/	O
Latin	O
American	O
Thoracic	O
Association	O
Statement	O
(	O
Raghu	O
et	O
al	O
.	O
2011	O
).	O

UIP	B-DS
pattern	O
was	O
defined	O
as	O
having	O
all	O
the	O
following	O
four	O
features	O
:	O
(	O
1	O
)	O
subpleural	O
,	O
basal	O
predominance	O
;	O
(	O
2	O
)	O
reticular	O
abnormality	O
;	O
(	O
3	O
)	O
honeycombing	O
with	O
or	O
without	O
traction	B-DS
bronchiectasis	I-DS
;	O
and	O
(	O
4	O
)	O
absence	O
of	O
features	O
listed	O
as	O
inconsistent	O
with	O
UIP	B-DS
pattern	O
(	O
Raghu	O
et	O
al	O
.	O
2011	O
).	O

If	O
honeycombing	O
was	O
absent	O
,	O
but	O
other	O
features	O
met	O
the	O
criteria	O
for	O
UIP	B-DS
,	O
the	O
case	O
was	O
classified	O
as	O
possible	O
UIP	B-DS
pattern	O
(	O
Raghu	O
et	O
al	O
.	O
2011	O
).	O

The	O
diagnosis	O
of	O
IPF	B-DS
was	O
based	O
on	O
the	O
following	O
criteria	O
:	O
(	O
1	O
)	O
UIP	B-DS
pattern	O
on	O
high	O
-	O
resolution	O
computed	O
tomography	O
and	O
(	O
2	O
)	O
exclusion	O
of	O
other	O
known	O
causes	O
of	O
interstitial	B-DS
lung	I-DS
diseases	I-DS
(	O
Raghu	O
et	O
al	O
.	O
2011	O
).	O

No	O
patients	O
in	O
this	O
study	O
underwent	O
surgical	O
lung	O
biopsy	O
to	O
diagnose	O
IPF	B-DS
.	O

According	O
to	O
the	O
sequential	O
reading	O
method	O
,	O
a	O
board	O
-	O
certificated	O
pulmonologist	O
(	O
N	O
.	O
K	O
.)	O
and	O
a	O
board	O
-	O
certificated	O
radiologist	O
(	O
M	O
.	O
M	O
.)	O
independently	O
reviewed	O
all	O
subjects	O
’	O
CT	O
scans	O
and	O
classified	O
them	O
into	O
four	O
categories	O
:	O
UIP	B-DS
pattern	O
,	O
possible	O
UIP	B-DS
pattern	O
,	O
inconsistent	O
with	O
UIP	B-DS
pattern	O
,	O
and	O
without	O
ILD	B-DS
.	O

Accordance	O
of	O
their	O
classifications	O
was	O
considered	O
a	O
definite	O
diagnosis	O
.	O

When	O
their	O
classifications	O
differed	O
,	O
two	O
other	O
board	O
-	O
certificated	O
pulmonologists	O
(	O
T	O
.	O
T	O
.	O
and	O
A	O
.	O
T	O
.)	O
carefully	O
reviewed	O
the	O
scans	O
independently	O
;	O
the	O
diagnosis	O
was	O
considered	O
definite	O
if	O
the	O
classifications	O
of	O
three	O
of	O
the	O
four	O
readers	O
were	O
in	O
accord	O
.	O

When	O
two	O
readers	O
agreed	O
on	O
one	O
classification	O
and	O
the	O
other	O
two	O
another	O
,	O
the	O
case	O
was	O
discussed	O
until	O
all	O
four	O
readers	O
agreed	O
on	O
a	O
diagnosis	O
(	O
this	O
procedure	O
was	O
required	O
in	O
two	O
cases	O
).	O

Diagnoses	O
of	O
AEs	O
of	O
ILD	B-DS
were	O
made	O
in	O
accordance	O
with	O
criteria	O
detailed	O
in	O
previous	O
studies	O
as	O
follows	O
:	O
(	O
1	O
)	O
worsening	O
of	O
dyspnea	O
within	O
30	O
days	O
;	O
(	O
2	O
)	O
new	O
radiologic	O
bilateral	O
ground	O
-	O
glass	O
abnormality	O
and	O
/	O
or	O
consolidation	O
superimposed	O
on	O
a	O
background	O
of	O
reticular	O
shadows	O
or	O
honeycombing	O
;	O
(	O
3	O
)	O
no	O
evidence	O
of	O
pulmonary	B-DS
infection	I-DS
;	O
and	O
(	O
4	O
)	O
exclusion	O
of	O
alternative	O
causes	O
,	O
including	O
left	B-DS
heart	I-DS
failure	I-DS
,	O
pulmonary	O
embolism	O
,	O
and	O
acute	O
lung	O
injury	O
of	O
identifiable	O
cause	O
(	O
Collard	O
et	O
al	O
.	O
2007	O
;	O
Kinoshita	O
et	O
al	O
.	O
2012	O
).	O

Statistical	O
analysis	O

PFS	O
was	O
defined	O
as	O
the	O
time	O
between	O
the	O
start	O
of	O
chemotherapy	O
or	O
molecular	O
targeted	O
therapy	O
and	O
diagnosis	O
of	O
disease	O
progression	O
or	O
death	O
.	O

OS	O
was	O
defined	O
as	O
the	O
time	O
between	O
the	O
date	O
of	O
diagnosis	O
and	O
date	O
of	O
death	O
from	O
any	O
cause	O
.	O

PFS	O
and	O
OS	O
curves	O
were	O
constructed	O
by	O
the	O
Kaplan	O
–	O
Meier	O
method	O
,	O
and	O
differences	O
in	O
survivals	O
compared	O
using	O
the	O
log	O
-	O
rank	O
test	O
.	O

Fisher	O
’	O
s	O
exact	O
test	O
and	O
Student	O
’	O
s	O
t	O
test	O
were	O
used	O
to	O
analyze	O
patient	O
characteristics	O
and	O
the	O
significance	O
of	O
the	O
association	O
of	O
AE	O
with	O
ILD	B-DS
or	O
IPF	B-DS
.	O

Laboratory	O
and	O
pulmonary	O
function	O
data	O
are	O
presented	O
as	O
mean	O
±	O
SD	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
Ekuseru	O
-	O
Toukei	O
2015	O
(	O
Social	O
Survey	O
Research	O
Information	O
,	O
Tokyo	O
,	O
Japan	O
).	O

Results	O

Patient	O
selection	O

In	O
all	O
,	O
285	O
patients	O
with	O
pathologically	O
confirmed	O
advanced	O
(	O
stage	O
IIIB	O
or	O
IV	O
)	O
NSCLC	B-DS
were	O
identified	O
for	O
this	O
study	O
,	O
29	O
of	O
whom	O
had	O
received	O
definitive	O
thoracic	O
irradiation	O
,	O
four	O
had	O
another	O
concomitant	O
active	O
malignancy	B-DS
(	O
malignant	B-DS
lymphoma	I-DS
,	O
renal	O
,	O
gastric	O
,	O
or	O
colon	B-DS
cancer	I-DS
),	O
and	O
34	O
had	O
received	O
only	O
best	O
supportive	O
care	O
.	O

Thus	O
,	O
218	O
patients	O
were	O
included	O
in	O
this	O
study	O
.	O

Samples	O
were	O
obtained	O
by	O
transbronchial	O
biopsy	O
(	O
131	O
cases	O
),	O
percutaneous	O
biopsy	O
(	O
71	O
cases	O
including	O
31	O
pleural	B-DS
effusions	I-DS
),	O
surgical	O
resection	O
(	O
9	O
cases	O
),	O
and	O
others	O
such	O
as	O
biopsy	O
at	O
different	O
departments	O
(	O
7	O
cases	O
).	O

Classification	O
of	O
ILD	B-DS
and	O
diagnosis	O
of	O
IPF	B-DS

Relevant	O
characteristics	O
of	O
patients	O
treated	O
with	O
chemotherapy	O
and	O
/	O
or	O
molecular	O
targeted	O
therapy	O
are	O
shown	O
in	O
Table	O
1	O
.	O

ILD	B-DS
was	O
identified	O
in	O
53	O
/	O
218	O
patients	O
(	O
24	O
.	O
3	O
%):	O
35	O
were	O
diagnosed	O
as	O
having	O
UIP	B-DS
,	O
15	O
possible	O
UIP	B-DS
,	O
and	O
three	O
inconsistent	O
with	O
UIP	B-DS
.	O

One	O
patient	O
had	O
dermatomyositis	B-DS
-	O
related	O
UIP	B-DS
pattern	O
,	O
and	O
the	O
remaining	O
34	O
with	O
UIP	B-DS
pattern	O
were	O
diagnosed	O
as	O
having	O
IPF	B-DS
(	O
15	O
.	O
6	O
%	O
of	O
218	O
patients	O
).	O
Table	O
1Characteristics	O
of	O
patients	O
treated	O
with	O
chemotherapy	O
and	O
/	O
or	O
molecular	O
targeted	O
therapyNon	O
-	O
ILD	B-DS
(	O
n	O
=	O
165	O
)	O
ILDAll	O
ILD	B-DS
(	O
n	O
=	O
53	O
)	O
P	O
(	O
vs	O
.	O
non	O
-	O
ILD	B-DS
)	O
IPF	B-DS
(	O
n	O
=	O
34	O
)	O
P	O
(	O
vs	O
.	O
non	O
-	O
ILD	B-DS
)	O
Age	O
,	O
years	O
(	O
range	O
)	O
66	O
(	O
30	O
–	O
91	O
)	O
71	O
(	O
57	O
–	O
86	O
)	O
0	O
.	O
0002770	O
(	O
57	O
–	O
86	O
)	O
0	O
.	O
0053Sex	O
Male95	O
(	O
58	O
%)	O
51	O
(	O
96	O
%)<	O
0	O
.	O
000134	O
(	O
100	O
%)<	O
0	O
.	O
0001	O
Female70	O
(	O
42	O
%)	O
2	O
(	O
4	O
%)	O
0	O
(	O
0	O
%)	O
Smoking	O
status	O
Never56	O
(	O
34	O
%)	O
2	O
(	O
4	O
%)<	O
0	O
.	O
00010	O
(	O
0	O
%)<	O
0	O
.	O
0001	O
Ever109	O
(	O
66	O
%)	O
51	O
(	O
96	O
%)	O
34	O
(	O
100	O
%)	O
Pack	O
-	O
year	O
,	O
average523467PS	O
0	O
–	O
1134	O
(	O
81	O
%)	O
43	O
(	O
81	O
%)	O
1	O
.	O
000027	O
(	O
79	O
%)	O
0	O
.	O
8123	O
2	O
–	O
431	O
(	O
19	O
%)	O
10	O
(	O
19	O
%)	O
7	O
(	O
21	O
%)	O
Histology	O
Adeno129	O
(	O
78	O
%)	O
21	O
(	O
40	O
%)<	O
0	O
.	O
000112	O
(	O
35	O
%)<	O
0	O
.	O
0001	O
Squamous22	O
(	O
13	O
%)	O
19	O
(	O
36	O
%)	O
0	O
.	O
000512	O
(	O
35	O
%)	O
0	O
.	O
0046	O
Adenosquamous122	O
Large121	O
Non	O
-	O
small1297Stage	O
IIIB1460	O
.	O
585431	O
.	O
0000	O
IV1514731EGFR	O
mutation	O
Yes53	O
(	O
32	O
%)	O
1	O
(	O
2	O
%)<	O
0	O
.	O
00010	O
(	O
0	O
%)<	O
0	O
.	O
0001	O
No112	O
(	O
68	O
%)	O
52	O
(	O
98	O
%)	O
34	O
(	O
100	O
%)	O
ILD	B-DS
interstitial	B-DS
lung	I-DS
disease	I-DS
,	O
IPF	B-DS
idiopathic	B-DS
pulmonary	I-DS
fibrosis	I-DS
,	O
PS	O
performance	O
status	O
,	O
EGFR	B-GP
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP

Patients	O
with	O
ILD	B-DS
were	O
significantly	O
older	O
than	O
those	O
without	O
ILD	B-DS
and	O
more	O
often	O
male	O
and	O
smokers	O
(	O
Table	O
1	O
).	O

The	O
frequency	O
of	O
adenocarcinoma	B-DS
was	O
lower	O
,	O
and	O
that	O
of	O
squamous	B-DS
cell	I-DS
carcinoma	I-DS
was	O
higher	O
in	O
patients	O
with	O
ILD	B-DS
than	O
in	O
those	O
without	O
it	O
(	O
40	O
vs	O
.	O
78	O
%	O
for	O
adenocarcinoma	B-DS
,	O
and	O
36	O
and	O
13	O
%	O
for	O
squamous	B-DS
cell	I-DS
carcinoma	I-DS
,	O
respectively	O
).	O
EGFR	B-GP
mutation	O
was	O
detected	O
in	O
53	O
/	O
112	O
non	O
-	O
ILD	B-DS
patients	O
(	O
32	O
%)	O
and	O
in	O
only	O
one	O
of	O
53	O
ILD	B-DS
patients	O
(	O
2	O
%).	O

These	O
differences	O
were	O
more	O
extreme	O
in	O
patients	O
with	O
IPF	B-DS
,	O
all	O
of	O
whom	O
were	O
male	O
smokers	O
.	O

Adenocarcinoma	B-DS
and	O
squamous	B-DS
cell	I-DS
carcinoma	I-DS
histology	O
each	O
comprised	O
35	O
%	O
of	O
cases	O
,	O
and	O
no	O
EGFR	B-GP
mutations	O
were	O
detected	O
.	O

Average	O
of	O
percent	O
vital	O
capacity	O
(%	O
VC	O
)	O
is	O
significantly	O
lower	O
in	O
IPF	B-DS
than	O
in	O
non	O
-	O
ILD	B-DS
patients	O
(	O
76	O
.	O
4	O
%	O
vs	O
89	O
.	O
1	O
%,	O
respectively	O
,	O
P	O
=	O
0	O
.	O
0115	O
,	O
data	O
not	O
shown	O
).	O

Responses	O
to	O
chemotherapy	O
and	O
/	O
or	O
molecular	O
targeted	O
therapy	O

First	O
-	O
line	O
therapy	O
was	O
cytotoxic	O
chemotherapy	O
in	O
179	O
/	O
218	O
patients	O
and	O
EGFR	B-GP
-	O
TKI	O
in	O
the	O
remaining	O
39	O
(	O
Table	O
2	O
).	O

Fewer	O
than	O
three	O
cycles	O
of	O
first	O
-	O
line	O
chemotherapy	O
were	O
received	O
by	O
72	O
and	O
82	O
%	O
of	O
ILD	B-DS
and	O
IPF	B-DS
patients	O
,	O
respectively	O
,	O
both	O
percentages	O
being	O
significantly	O
higher	O
than	O
for	O
non	O
-	O
ILD	B-DS
patients	O
(	O
37	O
%,	O
P	O
<	O
0	O
.	O
0001	O
).	O

RR	O
evaluated	O
by	O
RECIST	O
was	O
55	O
,	O
37	O
,	O
and	O
31	O
%	O
for	O
non	O
-	O
ILD	B-DS
,	O
ILD	B-DS
,	O
and	O
IPF	B-DS
patients	O
,	O
respectively	O
.	O

Disease	O
control	O
rate	O
(	O
DCR	O
)	O
was	O
87	O
,	O
71	O
,	O
and	O
53	O
%	O
in	O
non	O
-	O
ILD	B-DS
,	O
ILD	B-DS
,	O
and	O
IPF	B-DS
patients	O
,	O
respectively	O
.	O

RR	O
and	O
DCR	O
were	O
significantly	O
lower	O
in	O
ILD	B-DS
and	O
IPF	B-DS
patients	O
than	O
in	O
non	O
-	O
ILD	B-DS
patients	O
.	O

When	O
patients	O
with	O
EGFR	B-GP
mutation	O
were	O
excluded	O
(	O
n	O
=	O
54	O
),	O
RR	O
was	O
44	O
,	O
35	O
,	O
and	O
31	O
%	O
for	O
non	O
-	O
ILD	B-DS
,	O
ILD	B-DS
,	O
and	O
IPF	B-DS
patients	O
,	O
respectively	O
.	O

DCR	O
was	O
85	O
,	O
67	O
,	O
and	O
53	O
%	O
for	O
non	O
-	O
ILD	B-DS
,	O
ILD	B-DS
,	O
and	O
IPF	B-DS
patients	O
,	O
respectively	O
.	O

Although	O
RR	O
was	O
not	O
significantly	O
different	O
in	O
subjects	O
with	O
EGFR	B-GP
wild	O
type	O
(	O
WT	O
),	O
the	O
DCR	O
was	O
significantly	O
lower	O
in	O
ILD	B-DS
and	O
IPF	B-DS
than	O
in	O
non	O
-	O
ILD	B-DS
patients	O
.	O
Table	O
2Response	O
to	O
first	O
-	O
line	O
chemotherapy	O
/	O
molecular	O
targeted	O
therapyNon	O
-	O
ILD	B-DS
(	O
n	O
=	O
165	O
)	O
ILDAll	O
ILD	B-DS
(	O
n	O
=	O
53	O
)	O
P	O
(	O
vs	O
.	O
non	O
-	O
ILD	B-DS
)	O
IPF	B-DS
(	O
n	O
=	O
34	O
)	O
P	O
(	O
vs	O
.	O
non	O
-	O
ILD	B-DS
)	O
Number	O
of	O
cycles	O
of	O
chemotherapy	O
,	O
average	O
(	O
range	O
)	O
5	O
(	O
1	O
–	O
24	O
)	O
4	O
(	O
1	O
–	O
34	O
)	O
0	O
.	O
11213	O
(	O
1	O
–	O
12	O
)	O
0	O
.	O
0014Number	O
of	O
patients	O
who	O
received	O
fewer	O
than	O
three	O
cycles	O
(%)	O
61	O
(	O
37	O
%)	O
38	O
(	O
72	O
%)<	O
0	O
.	O
000128	O
(	O
82	O
%)<	O
0	O
.	O
0001All	O
patients	O
CR400	O
PR861910	O
SD51177	O
PD221515	O
NA222	O
Response	O
rate55	O
%	O
37	O
%	O
0	O
.	O
036331	O
%	O
0	O
.	O
0193	O
Disease	O
control	O
rate87	O
%	O
71	O
%	O
0	O
.	O
018053	O
%	O
0	O
.	O
0001Patients	O
without	O
EGFR	B-GP
mutation	O
CR200	O
PR461810	O
SD46177	O
PD161515	O
NA222	O
Response	O
rate44	O
%	O
35	O
%	O
0	O
.	O
391031	O
%	O
0	O
.	O
2278	O
Disease	O
control	O
rate85	O
%	O
67	O
%	O
0	O
.	O
030453	O
%	O
0	O
.	O
0004	O
ILD	B-DS
interstitial	B-DS
lung	I-DS
disease	I-DS
,	O
IPF	B-DS
idiopathic	B-DS
pulmonary	I-DS
fibrosis	I-DS
,	O
CR	O
complete	O
response	O
,	O
PR	O
partial	O
response	O
,	O
SD	O
stable	O
disease	O
,	O
PD	B-DS
progressive	B-DS
disease	I-DS
,	O
NA	O
not	O
assessed	O

Shorter	O
PFS	O
and	O
OS	O
in	O
patients	O
with	O
ILD	B-DS
or	O
IPF	B-DS

Kaplan	O
–	O
Meier	O
survival	O
curves	O
for	O
NSCLC	B-DS
patients	O
who	O
received	O
chemotherapy	O
and	O
/	O
or	O
molecular	O
targeted	O
therapy	O
showed	O
a	O
significantly	O
shorter	O
median	O
PFS	O
(	O
Fig	O
.	O
1a	O
,	O
118	O
vs	O
.	O
196	O
days	O
,	O
P	O
=	O
0	O
.	O
0007	O
)	O
and	O
OS	O
(	O
Fig	O
.	O
1b	O
,	O
267	O
vs	O
539	O
days	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
in	O
ILD	B-DS
than	O
in	O
non	O
-	O
ILD	B-DS
patients	O
.	O

In	O
patients	O
with	O
IPF	B-DS
,	O
median	O
PFS	O
(	O
92	O
days	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
OS	O
(	O
223	O
days	O
,	O
P	O
=	O
0	O
.	O
0002	O
)	O
were	O
even	O
shorter	O
(	O
Fig	O
.	O
2	O
).	O
Fig	O
.	O
1Kaplan	O
–	O
Meier	O
curves	O
of	O
(	O
a	O
)	O
progression	O
-	O
free	O
survival	O
and	O
(	O
b	O
)	O
overall	O
survival	O
in	O
advanced	O
NSCLC	B-DS
patients	O
with	O
interstitial	B-DS
lung	I-DS
disease	I-DS
(	O
ILD	B-DS
)	O
who	O
received	O
chemotherapy	O
and	O
/	O
or	O
molecular	O
targeted	O
therapyFig	O
.	O
2Kaplan	O
–	O
Meier	O
curves	O
of	O
(	O
a	O
)	O
progression	O
-	O
free	O
survival	O
and	O
(	O
b	O
)	O
overall	O
survival	O
in	O
advanced	O
NSCLC	B-DS
patients	O
with	O
idiopathic	B-DS
pulmonary	I-DS
fibrosis	I-DS
(	O
IPF	B-DS
)	O
who	O
received	O
chemotherapy	O
and	O
/	O
or	O
molecular	O
targeted	O
therapy	O

Univariate	O
analysis	O
by	O
the	O
log	O
-	O
rank	O
test	O
identified	O
that	O
male	O
sex	O
,	O
smoking	O
history	O
,	O
poor	O
performance	O
status	O
(	O
PS	O
),	O
non	O
-	O
adenocarcinoma	B-DS
histology	O
,	O
and	O
EGFR	B-GP
-	O
WT	O
were	O
associated	O
with	O
poor	O
PFS	O
and	O
/	O
or	O
OS	O
(	O
Table	O
3	O
).	O

Multivariate	O
analysis	O
by	O
Cox	O
proportional	O
hazards	O
model	O
showed	O
that	O
poor	O
PS	O
,	O
absence	O
of	O
EGFR	B-GP
mutation	O
,	O
and	O
presence	O
of	O
IPF	B-DS
were	O
identified	O
as	O
poor	O
prognostic	O
factors	O
for	O
PFS	O
and	O
OS	O
.	O
Table	O
3Risk	O
factors	O
associated	O
with	O
PFS	O
and	O
OS	O
n	O
PFSOSMedian	O
(	O
days	O
)	O
Univariate	O
analysisMultivariate	O
analysisMedian	O
(	O
days	O
)	O
Univariate	O
analysisMultivariate	O
analysis	O
P	O
valueHR	O
(	O
95	O
%	O
CI	O
)	O
P	O
value	O
P	O
valueHR	O
(	O
95	O
%	O
CI	O
)	O
P	O
valueAgeOlder	O
(≥	O
75	O
years	O
)	O
561500	O
.	O
08271	O
.	O
33	O
(	O
0	O
.	O
94	O
–	O
1	O
.	O
88	O
)	O
0	O
.	O
10823140	O
.	O
01451	O
.	O
46	O
(	O
1	O
.	O
00	O
–	O
2	O
.	O
15	O
)	O
0	O
.	O
0528Younger	O
(<	O
75	O
years	O
)	O
162186539Sex	O
Female722280	O
.	O
04031	O
.	O
05	O
(	O
0	O
.	O
67	O
–	O
1	O
.	O
67	O
)	O
0	O
.	O
82476380	O
.	O
00300	O
.	O
81	O
(	O
0	O
.	O
48	O
–	O
1	O
.	O
36	O
)	O
0	O
.	O
4219	O
Male146149398Smoking	O
status	O
Never582370	O
.	O
04050	O
.	O
84	O
(	O
0	O
.	O
52	O
–	O
1	O
.	O
33	O
)	O
0	O
.	O
45366100	O
.	O
02420	O
.	O
95	O
(	O
0	O
.	O
57	O
–	O
1	O
.	O
61	O
)	O
0	O
.	O
8595	O
Ever160149430PS	O
0	O
–	O
1178202	O
<	O
0	O
.	O
00010	O
.	O
35	O
(	O
0	O
.	O
24	O
–	O
0	O
.	O
52	O
)<	O
0	O
.	O
0001538	O
<	O
0	O
.	O
00010	O
.	O
24	O
(	O
0	O
.	O
16	O
–	O
0	O
.	O
36	O
)<	O
0	O
.	O
0001	O
2	O
–	O
44079139Histology	O
Adeno1501900	O
.	O
04301	O
.	O
02	O
(	O
0	O
.	O
71	O
–	O
1	O
.	O
47	O
)	O
0	O
.	O
89545390	O
.	O
00091	O
.	O
00	O
(	O
0	O
.	O
67	O
–	O
1	O
.	O
49	O
)	O
0	O
.	O
9929	O
Others68150283Stage	O
IIIB201850	O
.	O
72030	O
.	O
78	O
(	O
0	O
.	O
47	O
–	O
1	O
.	O
28	O
)	O
0	O
.	O
32464950	O
.	O
94070	O
.	O
90	O
(	O
0	O
.	O
52	O
–	O
1	O
.	O
56	O
)	O
0	O
.	O
7136	O
IV198180471EGFR	O
mutation	O
Yes543040	O
.	O
00030	O
.	O
55	O
(	O
0	O
.	O
37	O
–	O
0	O
.	O
82	O
)	O
0	O
.	O
00377710	O
.	O
00010	O
.	O
51	O
(	O
0	O
.	O
33	O
–	O
0	O
.	O
81	O
)	O
0	O
.	O
0042	O
No164149360ILD	O
IPF34920	O
.	O
000021	O
.	O
98	O
(	O
1	O
.	O
26	O
–	O
3	O
.	O
11	O
)	O
0	O
.	O
00302230	O
.	O
00021	O
.	O
74	O
(	O
1	O
.	O
03	O
–	O
2	O
.	O
92	O
)	O
0	O
.	O
0373	O
Non	O
-	O
ILD165196539	O
PFS	O
progression	O
-	O
free	O
survival	O
,	O
OS	O
overall	O
survival	O
,	O
HR	O
hazard	O
ratio	O
,	O
PS	O
performance	O
status	O
,	O
EGFR	B-GP
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
,	O
ILD	B-DS
interstitial	B-DS
lung	I-DS
disease	I-DS
,	O
IPF	B-DS
idiopathic	O
pulmonary	O
fibrosisTable	O
4Associations	O
between	O
chemotherapeutic	O
regimens	O
and	O
acute	O
exacerbation	O
of	O
ILD	B-DS
and	O
IPFILDIPF	O
n	O
AE	O
(−)	O
AE	O
(+)	O
Incidence	O
(%)	O
P	O
value	O
n	O
AE	O
(−)	O
AE	O
(+)	O
Incidence	O
(%)	O
P	O
valueDocetaxel	O
Containing3831718	O
.	O
40	O
.	O
04722419520	O
.	O
80	O
.	O
0802	O
Not	O
containing585535	O
.	O
2292813	O
.	O
4Pemetrexed	O
Containing1513213	O
.	O
30	O
.	O
653187112	O
.	O
51	O
.	O
0000	O
Not	O
containing817389	O
.	O
94540511	O
.	O
1Paclitaxel	O
/	O
nab	O
-	O
paclitaxel	O
Containing121200	O
.	O
00	O
.	O
35335500	O
.	O
01	O
.	O
0000	O
Not	O
containing84741011	O
.	O
94842612	O
.	O
5	O
ILD	B-DS
interstitial	B-DS
lung	I-DS
disease	I-DS
,	O
IPF	B-DS
idiopathic	B-DS
pulmonary	I-DS
fibrosis	I-DS
,	O
AE	O
acute	O
exacerbation	O

Because	O
EGFR	B-GP
mutation	O
status	O
is	O
associated	O
with	O
survival	O
and	O
differs	O
between	O
non	O
-	O
ILD	B-DS
and	O
ILD	B-DS
/	O
IPF	B-DS
patients	O
,	O
PFS	O
and	O
OS	O
were	O
assessed	O
in	O
these	O
patients	O
.	O

Interestingly	O
,	O
PFS	O
and	O
OS	O
were	O
still	O
shorter	O
in	O
ILD	B-DS
and	O
IPF	B-DS
patients	O
with	O
EGFR	B-GP
-	O
WT	O
.	O

Median	O
PFS	O
was	O
180	O
,	O
118	O
,	O
and	O
92	O
days	O
for	O
non	O
-	O
ILD	B-DS
,	O
ILD	B-DS
,	O
and	O
IPF	B-DS
patients	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
0301	O
for	O
non	O
-	O
ILD	B-DS
vs	O
.	O
ILD	B-DS
and	O
P	O
=	O
0	O
.	O
0018	O
for	O
non	O
-	O
ILD	B-DS
vs	O
.	O
IPF	B-DS
).	O

Median	O
OS	O
was	O
458	O
,	O
258	O
,	O
and	O
223	O
days	O
for	O
non	O
-	O
ILD	B-DS
,	O
ILD	B-DS
,	O
and	O
IPF	B-DS
patients	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
0202	O
for	O
non	O
-	O
ILD	B-DS
vs	O
.	O
ILD	B-DS
and	O
P	O
=	O
0	O
.	O
0126	O
for	O
non	O
-	O
ILD	B-DS
vs	O
.	O
IPF	B-DS
).	O

Factors	O
associated	O
with	O
AEs	O
of	O
ILD	B-DS

AEs	O
were	O
observed	O
in	O
10	O
/	O
53	O
patients	O
(	O
18	O
.	O
9	O
%)	O
with	O
ILD	B-DS
(	O
Table	O
5	O
).	O

Limited	O
to	O
patients	O
with	O
IPF	B-DS
,	O
AEs	O
developed	O
in	O
6	O
/	O
34	O
patients	O
(	O
17	O
.	O
6	O
%).	O

No	O
factors	O
associated	O
with	O
the	O
occurrence	O
of	O
AE	O
were	O
identified	O
.	O

However	O
,	O
the	O
incidence	O
of	O
AEs	O
differed	O
between	O
chemotherapeutic	O
regimens	O
(	O
Table	O
4	O
).	O

The	O
number	O
of	O
regimen	O
types	O
received	O
by	O
each	O
patient	O
was	O
counted	O
as	O
shown	O
by	O
the	O
following	O
example	O
:	O
carboplatin	O
plus	O
pemetrexed	O
plus	O
bevacizumab	O
followed	O
by	O
pemetrexed	O
plus	O
bevacizumab	O
was	O
classified	O
as	O
one	O
regimen	O
type	O
.	O

The	O
same	O
regimen	O
administered	O
to	O
two	O
patients	O
was	O
counted	O
as	O
two	O
regimens	O
.	O

In	O
all	O
,	O
96	O
regimens	O
were	O
administered	O
to	O
53	O
patients	O
with	O
ILD	B-DS
.	O

When	O
they	O
contained	O
docetaxel	O
,	O
the	O
incidence	O
of	O
AEs	O
was	O
18	O
.	O
4	O
%	O
(	O
7	O
/	O
38	O
regimens	O
),	O
which	O
is	O
significantly	O
higher	O
than	O
for	O
regimens	O
without	O
docetaxel	O
(	O
5	O
.	O
2	O
%,	O
P	O
=	O
0	O
.	O
0472	O
).	O

In	O
IPF	B-DS
patients	O
,	O
docetaxel	O
-	O
containing	O
regimens	O
resulted	O
in	O
a	O
trend	O
toward	O
higher	O
incidence	O
of	O
AEs	O
(	O
5	O
/	O
24	O
patients	O
;	O
20	O
.	O
8	O
%),	O
whereas	O
only	O
1	O
/	O
29	O
regimens	O
(	O
3	O
.	O
4	O
%)	O
without	O
docetaxel	O
led	O
to	O
AEs	O
(	O
P	O
=	O
0	O
.	O
0802	O
);	O
this	O
difference	O
is	O
not	O
statistically	O
significant	O
.	O

No	O
ILD	B-DS
patients	O
received	O
EGFR	B-GP
-	O
TKI	O
.	O
Table	O
5Patient	O
characteristics	O
associated	O
with	O
acute	O
exacerbations	O
of	O
ILD	B-DS
and	O
IPFILDIPFAE	O
(−)	O
(	O
n	O
=	O
43	O
)	O
AE	O
(+)	O
(	O
n	O
=	O
10	O
)	O
P	O
valueAE	O
(−)	O
(	O
n	O
=	O
28	O
)	O
AE	O
(+)	O
(	O
n	O
=	O
6	O
)	O
P	O
valueAge	O
Older	O
(≥	O
75	O
years	O
)	O
1350	O
.	O
2792930	O
.	O
6410	O
Younger	O
(<	O
75	O
years	O
)	O
305193Sex	O
Female110	O
.	O
3447001	O
.	O
0000	O
Male429286Smoking	O
status	O
Never110	O
.	O
3447001	O
.	O
0000	O
Ever429286PS	O
0	O
–	O
13670	O
.	O
37612340	O
.	O
5798	O
2	O
–	O
47352Histology	O
Adeno1950	O
.	O
74111021	O
.	O
0000	O
Others245184Stage	O
IIIB511	O
.	O
0000301	O
.	O
0000	O
IV389256EGFR	O
mutation	O
Yes010	O
.	O
1887001	O
.	O
0000	O
No439286LDH283	B-GP
±	O
127314	O
±	O
1260	O
.	O
5208277	O
±	O
114340	O
±	O
1430	O
.	O
3829KL	B-GP
-	I-GP
6808	I-GP
±	O
608688	O
±	O
3720	O
.	O
5435865	O
±	O
664807	O
±	O
4600	O
.	O
8625	O
%	O
VC81	O
.	O
8	O
±	O
19	O
.	O
884	O
.	O
4	O
±	O
18	O
.	O
50	O
.	O
742678	O
.	O
0	O
±	O
18	O
.	O
071	O
.	O
6	O
±	O
13	O
.	O
80	O
.	O
4691	O
%	O
FVC79	O
.	O
7	O
±	O
20	O
.	O
280	O
.	O
6	O
±	O
18	O
.	O
70	O
.	O
908578	O
.	O
1	O
±	O
18	O
.	O
367	O
.	O
2	O
±	O
13	O
.	O
80	O
.	O
2263	O
ILD	B-DS
interstitial	B-DS
lung	I-DS
disease	I-DS
,	O
IPF	B-DS
idiopathic	B-DS
pulmonary	I-DS
fibrosis	I-DS
,	O
AE	O
acute	O
exacerbation	O
,	O
PS	O
performance	O
status	O
,	O
EGFR	B-GP
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
,	O
LDH	B-GP
lactate	B-GP
dehydrogenase	I-GP
,	O
VC	O
vital	O
capacity	O
,	O
FVC	O
forced	O
vital	O
capacity	O

Median	O
PFS	O
in	O
patients	O
with	O
and	O
without	O
AE	O
was	O
118	O
versus	O
124	O
days	O
(	O
P	O
=	O
0	O
.	O
4244	O
),	O
and	O
median	O
OS	O
was	O
142	O
versus	O
284	O
days	O
(	O
P	O
=	O
0	O
.	O
1099	O
).	O

Although	O
these	O
differences	O
are	O
not	O
statistically	O
significant	O
,	O
6	O
/	O
10	O
patients	O
died	O
quickly	O
after	O
the	O
onset	O
of	O
their	O
AEs	O
(	O
Table	O
6	O
).	O

All	O
patients	O
who	O
developed	O
AEs	O
were	O
treated	O
with	O
corticosteroids	O
,	O
including	O
methylprednisolone	O
pulse	O
therapy	O
,	O
and	O
received	O
no	O
further	O
chemotherapy	O
.	O
Table	O
6Outcomes	O
of	O
ten	O
patients	O
with	O
acute	O
exacerbations	O
of	O
ILDNo	O
.	O
Classification	O
of	O
ILDAssociated	O
regimens	O
(	O
chemotherapeutic	O
line	O
)	O
Cycles	O
receivedOnset	O
of	O
AE	O
(	O
days	O
from	O
chemotherapy	O
)	O
Outcome	O
of	O
AESurvival	O
(	O
days	O
from	O
onset	O
of	O
AE	O
)	O
1Possible	O
UIPPemetrexed	O
(	O
second	O
)	O
113Died162Inconsistent	O
with	O
UIPS	O
-	O
1	O
(	O
third	O
)	O
126Died23Possible	O
UIPCarboplatin	O
and	O
docetaxel	O
(	O
first	O
)	O
5150Died364IPFCarboplatin	O
and	O
docetaxel	O
(	O
first	O
)	O
115Died125IPFCarboplatin	O
and	O
pemetrexed	O
(	O
first	O
)	O
241Recovered816IPFCarboplatin	O
and	O
docetaxel	O
(	O
first	O
)	O
322Died47IPFDocetaxel	O
(	O
first	O
)	O
252Recovered808IPFDocetaxel	O
(	O
first	O
)	O
246Died49Possible	O
UIPDocetaxel	O
(	O
second	O
)	O
228Recovered38510IPFDocetaxel	O
(	O
first	O
)	O
118Recovered108	O
ILD	B-DS
interstitial	B-DS
lung	I-DS
disease	I-DS
,	O
UIP	B-DS
usual	B-DS
interstitial	I-DS
pneumonia	I-DS
,	O
IPF	B-DS
idiopathic	B-DS
pulmonary	I-DS
fibrosis	I-DS
,	O
AE	O
acute	O
exacerbation	O

The	O
reasons	O
for	O
discontinuation	O
of	O
first	O
-	O
line	O
chemotherapy	O
within	O
three	O
cycles	O
were	O
investigated	O
(	O
Table	O
7	O
).	O

Interestingly	O
,	O
discontinuation	O
because	O
of	O
adverse	O
events	O
occurred	O
significantly	O
more	O
often	O
in	O
ILD	B-DS
and	O
IPF	B-DS
than	O
in	O
non	O
-	O
ILD	B-DS
patients	O
(	O
42	O
,	O
46	O
,	O
and	O
21	O
%,	O
respectively	O
).	O

Importantly	O
,	O
6	O
/	O
16	O
adverse	O
events	O
that	O
resulted	O
in	O
discontinuation	O
of	O
chemotherapy	O
were	O
AEs	O
in	O
ILD	B-DS
patients	O
.	O

In	O
IPF	B-DS
patients	O
,	O
AEs	O
comprise	O
6	O
/	O
13	O
adverse	O
events	O
.	O
Table	O
7Reasons	O
for	O
discontinuation	O
of	O
first	O
-	O
line	O
chemotherapy	O
within	O
three	O
cyclesNon	O
-	O
ILD	B-DS
(	O
n	O
=	O
61	O
)	O
ILDAll	O
ILD	B-DS
(	O
n	O
=	O
38	O
)	O
P	O
(	O
vs	O
.	O
non	O
-	O
ILD	B-DS
)	O
IPF	B-DS
(	O
n	O
=	O
28	O
)	O
P	O
(	O
vs	O
.	O
non	O
-	O
ILD	B-DS
)	O
PD21	O
(	O
34	O
%)	O
14	O
(	O
37	O
%)	O
0	O
.	O
831613	O
(	O
46	O
%)	O
0	O
.	O
3490Deterioration	O
in	O
PS12	O
(	O
20	O
%)	O
7	O
(	O
18	O
%)	O
1	O
.	O
00005	O
(	O
18	O
%)	O
1	O
.	O
0000Adverse	O
events13	O
(	O
21	O
%)	O
16	O
(	O
42	O
%)	O
0	O
.	O
040313	O
(	O
46	O
%)	O
0	O
.	O
0234Acute	O
exacerbation	O
–	O
66Others16	O
(	O
26	O
%)	O
4	O
(	O
11	O
%)	O
0	O
.	O
07351	O
(	O
4	O
%)	O
0	O
.	O
0100	O
Note	O
Because	O
numbers	O
are	O
shown	O
as	O
events	O
,	O
the	O
total	O
number	O
may	O
exceed	O
patient	O
numbers	O
and	O
the	O
total	O
percentage	O
will	O
exceed	O
100	O
%	O
ILD	B-DS
interstitial	B-DS
lung	I-DS
disease	I-DS
,	O
IPF	B-DS
idiopathic	B-DS
pulmonary	I-DS
fibrosis	I-DS
,	O
PD	B-DS
progressive	B-DS
disease	I-DS
,	O
PS	O
performance	O
status	O

Discussion	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
(	O
1	O
)	O
characteristics	O
of	O
ILD	B-DS
/	O
IPF	B-DS
patients	O
differed	O
significantly	O
from	O
those	O
of	O
non	O
-	O
ILD	B-DS
patients	O
;	O
in	O
particular	O
,	O
no	O
IPF	B-DS
patients	O
had	O
EGFR	B-GP
mutation	O
-	O
positive	O
tumors	B-DS
;	O
(	O
2	O
)	O
the	O
presence	O
of	O
either	O
IPF	B-DS
or	O
ILD	B-DS
was	O
associated	O
with	O
shorter	O
PFS	O
and	O
OS	O
in	O
patients	O
with	O
advanced	O
NSCLC	B-DS
who	O
received	O
chemotherapy	O
;	O
(	O
3	O
)	O
DCR	O
was	O
significantly	O
lower	O
in	O
ILD	B-DS
and	O
IPF	B-DS
patients	O
than	O
in	O
non	O
-	O
ILD	B-DS
patients	O
,	O
even	O
those	O
with	O
EGFR	B-GP
-	O
WT	O
;	O
and	O
(	O
4	O
)	O
AEs	O
of	O
ILD	B-DS
occurred	O
more	O
frequently	O
after	O
docetaxel	O
-	O
containing	O
regimens	O
than	O
after	O
other	O
regimens	O
.	O

The	O
present	O
study	O
clearly	O
demonstrated	O
several	O
differences	O
in	O
the	O
characteristics	O
of	O
non	O
-	O
ILD	B-DS
and	O
ILD	B-DS
/	O
IPF	B-DS
patients	O
.	O

Most	O
ILD	B-DS
and	O
all	O
34	O
IPF	B-DS
patients	O
were	O
male	O
smokers	O
and	O
had	O
EGFR	B-GP
-	O
WT	O
.	O

It	O
is	O
particularly	O
interesting	O
that	O
no	O
IPF	B-DS
patients	O
had	O
EGFR	B-GP
mutation	O
-	O
positive	O
cancers	B-DS
,	O
which	O
has	O
been	O
shown	O
for	O
the	O
first	O
time	O
although	O
a	O
previous	O
study	O
has	O
reported	O
a	O
correlation	O
between	O
preexisting	O
ILD	B-DS
and	O
EGFR	B-GP
-	O
WT	O
adenocarcinoma	B-DS
(	O
Fujimoto	O
et	O
al	O
.	O
2013	O
).	O

In	O
that	O
study	O
,	O
only	O
one	O
of	O
31	O
ILD	B-DS
patients	O
with	O
lung	B-DS
adenocarcinoma	I-DS
had	O
an	O
EGFR	B-GP
mutation	O
;	O
this	O
patient	O
had	O
a	O
non	O
-	O
UIP	B-DS
radiographic	O
pattern	O
(	O
Fujimoto	O
et	O
al	O
.	O
2013	O
).	O

The	O
current	O
study	O
extended	O
this	O
finding	O
in	O
that	O
our	O
one	O
ILD	B-DS
patient	O
with	O
EGFR	B-GP
mutation	O
also	O
had	O
a	O
radiologic	O
pattern	O
inconsistent	O
with	O
UIP	B-DS
pattern	O
.	O

The	O
frequency	O
of	O
squamous	B-DS
cell	I-DS
carcinoma	I-DS
was	O
higher	O
in	O
IPF	B-DS
than	O
in	O
non	O
-	O
ILD	B-DS
patients	O
(	O
35	O
vs	O
.	O
13	O
%).	O

In	O
ILD	B-DS
patients	O
,	O
most	O
tumors	B-DS
reportedly	O
develop	O
in	O
the	O
area	O
affected	O
by	O
ILD	B-DS
(	O
Fujimoto	O
et	O
al	O
.	O
2013	O
;	O
Kanaji	O
et	O
al	O
.	O
2015	O
).	O

The	O
current	O
study	O
provides	O
evidence	O
that	O
carcinogenesis	O
in	O
IPF	B-DS
differs	O
from	O
that	O
in	O
non	O
-	O
ILD	B-DS
patients	O
in	O
that	O
it	O
is	O
not	O
associated	O
with	O
EGFR	B-GP
mutation	O
.	O

Consistent	O
with	O
previous	O
studies	O
(	O
Borchers	O
et	O
al	O
.	O
2011	O
;	O
Watanabe	O
et	O
al	O
.	O
2013	O
),	O
IPF	B-DS
was	O
the	O
commonest	O
type	O
of	O
ILD	B-DS
(	O
34	O
/	O
53	O
patients	O
;	O
64	O
%).	O

Even	O
in	O
patients	O
with	O
EGFR	B-GP
-	O
WT	O
,	O
PFS	O
and	O
OS	O
were	O
significantly	O
shorter	O
in	O
IPF	B-DS
than	O
in	O
non	O
-	O
ILD	B-DS
patients	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
presence	O
of	O
IPF	B-DS
predicts	O
an	O
extremely	O
poor	O
prognosis	O
in	O
patients	O
with	O
advanced	O
NSCLC	B-DS
.	O

Lower	O
%	O
VC	O
(<	O
80	O
%)	O
was	O
also	O
associated	O
with	O
shorter	O
survivals	O
(	O
120	O
vs	O
196	O
days	O
for	O
PFS	O
,	O
P	O
=	O
0	O
.	O
0043	O
,	O
and	O
266	O
vs	O
538	O
days	O
for	O
OS	O
,	O
P	O
=	O
0	O
.	O
0023	O
,	O
respectively	O
,	O
data	O
not	O
shown	O
).	O

Shorter	O
survival	O
in	O
lower	O
%	O
VC	O
has	O
been	O
reported	O
in	O
patients	O
with	O
NSCLC	B-DS
and	O
ILD	B-DS
who	O
underwent	O
surgical	O
resection	O
(	O
Sato	O
et	O
al	O
.	O
2015	O
).	O

Another	O
important	O
finding	O
of	O
the	O
current	O
study	O
is	O
regarding	O
response	O
to	O
chemotherapy	O
/	O
molecular	O
targeted	O
therapy	O
.	O

RR	O
and	O
DCR	O
in	O
ILD	B-DS
/	O
IPF	B-DS
patients	O
were	O
lower	O
than	O
that	O
in	O
non	O
-	O
ILD	B-DS
patients	O
.	O
EGFR	B-GP
mutation	O
was	O
not	O
identified	O
in	O
any	O
of	O
the	O
34	O
IPF	B-DS
patients	O
,	O
whereas	O
32	O
%	O
of	O
non	O
-	O
ILD	B-DS
patients	O
harbored	O
EGFR	B-GP
mutations	O
.	O

Because	O
the	O
response	O
to	O
EGFR	B-GP
-	O
TKI	O
is	O
much	O
better	O
in	O
tumors	B-DS
with	O
EGFR	B-GP
mutation	O
than	O
in	O
EGFR	B-GP
-	O
WT	O
,	O
the	O
lower	O
RR	O
in	O
IPF	B-DS
patients	O
may	O
be	O
associated	O
with	O
the	O
absence	O
of	O
EGFR	B-GP
mutations	O
.	O

Indeed	O
,	O
the	O
difference	O
in	O
RR	O
was	O
not	O
significant	O
for	O
EGFR	B-GP
-	O
WT	O
patients	O
;	O
interestingly	O
,	O
however	O
,	O
a	O
difference	O
in	O
DCR	O
was	O
observed	O
,	O
even	O
in	O
patients	O
without	O
EGFR	B-GP
mutations	O
.	O

There	O
are	O
several	O
possible	O
mechanisms	O
that	O
could	O
explain	O
the	O
lower	O
DCR	O
and	O
shorter	O
survival	O
of	O
ILD	B-DS
/	O
IPF	B-DS
patients	O
.	O

First	O
,	O
ILD	B-DS
/	O
IPF	B-DS
patients	O
may	O
experience	O
adverse	O
events	O
more	O
frequently	O
.	O

Indeed	O
,	O
adverse	O
events	O
,	O
including	O
AEs	O
,	O
and	O
PD	B-DS
were	O
the	O
main	O
reasons	O
for	O
discontinuing	O
first	O
-	O
line	O
therapy	O
within	O
three	O
cycles	O
in	O
patients	O
with	O
ILD	B-DS
/	O
IPF	B-DS
,	O
suggesting	O
that	O
AEs	O
of	O
ILD	B-DS
/	O
IPF	B-DS
may	O
have	O
made	O
an	O
important	O
contribution	O
to	O
the	O
lower	O
DCR	O
and	O
shorter	O
survival	O
.	O

Consistent	O
with	O
this	O
,	O
coexisting	O
ILD	B-DS
is	O
reportedly	O
associated	O
with	O
a	O
high	O
risk	O
of	O
developing	O
chemotherapy	O
-	O
induced	O
ILD	B-DS
(	O
Sakurada	O
et	O
al	O
.	O
2015	O
).	O

Chemotherapeutic	O
strategies	O
that	O
do	O
not	O
induce	O
AEs	O
or	O
deterioration	O
of	O
ILD	B-DS
are	O
needed	O
.	O

Second	O
,	O
an	O
altered	O
drug	O
delivery	O
system	O
may	O
lead	O
to	O
the	O
lower	O
response	O
and	O
shorter	O
survival	O
of	O
ILD	B-DS
/	O
IPF	B-DS
patients	O
.	O

Histological	O
features	O
of	O
the	O
UIP	B-DS
pattern	O
include	O
marked	O
pulmonary	B-DS
fibrosis	I-DS
and	O
architectural	O
distortion	O
(	O
Raghu	O
et	O
al	O
.	O
2011	O
).	O

Alveolar	O
epithelial	O
cell	O
damage	O
,	O
dysregulation	O
of	O
fibroblasts	O
,	O
and	O
vascular	O
injury	O
and	O
aberrant	O
angiogenesis	O
related	O
to	O
vascular	O
remodeling	O
are	O
key	O
elements	O
of	O
lung	B-DS
fibrosis	I-DS
(	O
Selman	O
and	O
Pardo	O
2006	O
;	O
Wémeau	O
-	O
Stervinou	O
et	O
al	O
.	O
2012	O
).	O

Destruction	O
of	O
normal	O
vasculature	O
would	O
logically	O
reduce	O
the	O
local	O
delivery	O
of	O
chemotherapeutic	O
agents	O
to	O
a	O
tumor	B-DS
.	O

Third	O
,	O
acquired	O
drug	O
resistance	O
may	O
result	O
in	O
lower	O
DCR	O
and	O
shorter	O
survival	O
in	O
ILD	B-DS
/	O
IPF	B-DS
patients	O
.	O

In	O
this	O
regard	O
,	O
transforming	B-GP
growth	I-GP
factor	I-GP
(	B-GP
TGF	I-GP
)-	I-GP
β	I-GP
may	O
have	O
a	O
role	O
.	O

Many	O
cytokines	B-GP
and	O
growth	O
factors	O
,	O
including	O
TGF	B-GP
-	I-GP
β	I-GP
,	O
are	O
reportedly	O
associated	O
with	O
the	O
development	O
of	O
ILD	B-DS
/	O
IPF	B-DS
(	O
Das	O
et	O
al	O
.	O
2014	O
;	O
Kanaji	O
et	O
al	O
.	O
2014	O
).	O

TGF	B-GP
-	I-GP
β	I-GP
concentrations	O
are	O
higher	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
obtained	O
from	O
IPF	B-DS
than	O
from	O
control	O
patients	O
(	O
Khalil	O
et	O
al	O
.	O
2001	O
).	O

TGF	B-GP
-	I-GP
β	I-GP
is	O
reportedly	O
associated	O
with	O
chemoresistance	O
in	O
colon	B-DS
cancer	I-DS
(	O
Li	O
et	O
al	O
.	O
2015	O
).	O

Additionally	O
,	O
TGF	B-GP
-	I-GP
β	I-GP
is	O
a	O
major	O
regulator	O
of	O
epithelial	O
–	O
mesenchymal	O
transition	O
in	O
the	O
alveolar	O
epithelia	O
(	O
Kasai	O
et	O
al	O
.	O
2005	O
;	O
Miyazono	O
2009	O
).	O

In	O
epithelial	O
–	O
mesenchymal	O
transition	O
,	O
cancer	B-DS
cells	O
seemingly	O
acquire	O
chemoresistance	O
in	O
lung	O
and	O
other	O
types	O
of	O
cancers	B-DS
(	O
Jiang	O
et	O
al	O
.	O
2015	O
;	O
Li	O
et	O
al	O
.	O
2014	O
;	O
Wang	O
et	O
al	O
.	O
2015	O
).	O

Thus	O
,	O
increased	O
TGF	B-GP
-	I-GP
β	I-GP
in	O
the	O
lung	O
’	O
s	O
microenvironment	O
may	O
be	O
a	O
causative	O
factor	O
for	O
lower	O
DCR	O
and	O
shorter	O
survival	O
in	O
NSCLC	B-DS
patients	O
with	O
ILD	B-DS
/	O
IPF	B-DS
.	O

Regarding	O
AEs	O
of	O
ILD	B-DS
,	O
several	O
studies	O
have	O
reported	O
docetaxel	O
-	O
induced	O
AE	O
(	O
Tamiya	O
et	O
al	O
.	O
2012	O
;	O
Watanabe	O
et	O
al	O
.	O
2015	O
).	O

In	O
35	O
patients	O
with	O
NSCLC	B-DS
and	O
IP	B-DS
treated	O
with	O
docetaxel	O
monotherapy	O
,	O
the	O
incidence	O
of	O
AEs	O
of	O
IP	B-DS
was	O
14	O
.	O
3	O
%	O
(	O
5	O
/	O
35	O
patients	O
).	O

Three	O
of	O
the	O
five	O
patients	O
who	O
developed	O
AEs	O
of	O
IP	B-DS
died	O
(	O
Watanabe	O
et	O
al	O
.	O
2015	O
).	O

In	O
another	O
study	O
,	O
deterioration	O
of	O
ILD	B-DS
was	O
observed	O
in	O
7	O
/	O
27	O
patients	O
(	O
25	O
.	O
9	O
%)	O
with	O
NSCLC	B-DS
and	O
preexisting	O
ILD	B-DS
(	O
Tamiya	O
et	O
al	O
.	O
2012	O
).	O

In	O
contrast	O
,	O
6	O
/	O
309	O
patients	O
(	O
1	O
.	O
9	O
%)	O
without	O
preexisting	O
ILD	B-DS
reportedly	O
developed	O
it	O
after	O
receiving	O
docetaxel	O
(	O
Tamiya	O
et	O
al	O
.	O
2012	O
).	O

In	O
the	O
current	O
study	O
,	O
there	O
was	O
also	O
a	O
higher	O
incidence	O
of	O
AEs	O
of	O
ILD	B-DS
/	O
IPF	B-DS
after	O
docetaxel	O
-	O
containing	O
chemotherapy	O
.	O

Of	O
note	O
,	O
AEs	O
also	O
occurred	O
in	O
3	O
/	O
15	O
patients	O
with	O
radiographic	O
possible	O
UIP	B-DS
pattern	O
(	O
20	O
%).	O

Several	O
studies	O
have	O
reported	O
that	O
possible	O
UIP	B-DS
pattern	O
often	O
corresponds	O
with	O
pathologically	O
confirmed	O
UIP	B-DS
(	O
Sumikawa	O
et	O
al	O
.	O
2014	O
;	O
Raghu	O
et	O
al	O
.	O
2014	O
).	O

Radiographic	O
possible	O
UIP	B-DS
pattern	O
should	O
be	O
considered	O
clinically	O
similar	O
to	O
UIP	B-DS
when	O
choosing	O
treatment	O
strategies	O
for	O
patients	O
with	O
advanced	O
NSCLC	B-DS
.	O

Administration	O
schedule	O
also	O
affects	O
the	O
incidence	O
of	O
AEs	O
(	O
higher	O
incidence	O
in	O
a	O
weekly	O
than	O
in	O
triweekly	O
administration	O
)	O
(	O
Chen	O
et	O
al	O
.	O
2006	O
).	O

Anti	O
-	O
microtubule	O
activity	O
by	O
taxanes	O
itself	O
seems	O
not	O
to	O
be	O
related	O
in	O
the	O
development	O
of	O
AE	O
because	O
the	O
incidence	O
of	O
AE	O
in	O
paclitaxel	O
is	O
different	O
from	O
that	O
in	O
docetaxel	O
.	O

Thus	O
,	O
factors	O
other	O
than	O
anticancer	O
activity	O
might	O
be	O
associated	O
with	O
docetaxel	O
-	O
related	O
AE	O
although	O
an	O
actual	O
mechanism	O
has	O
never	O
been	O
reported	O
.	O

No	O
optimal	O
chemotherapeutic	O
regimen	O
for	O
patients	O
with	O
advanced	O
NSCLC	B-DS
and	O
underlying	O
ILD	B-DS
has	O
been	O
established	O
(	O
Watanabe	O
et	O
al	O
.	O
2015	O
).	O

A	O
combination	O
of	O
carboplatin	O
and	O
weekly	O
paclitaxel	O
may	O
be	O
a	O
treatment	O
option	O
for	O
NSCLC	B-DS
with	O
ILD	B-DS
(	O
Minegishi	O
et	O
al	O
.	O
2011	O
).	O

Eighteen	O
patients	O
with	O
ILD	B-DS
,	O
including	O
six	O
with	O
IPF	B-DS
,	O
treated	O
with	O
carboplatin	O
and	O
paclitaxel	O
achieved	O
PFS	O
and	O
median	O
survival	O
time	O
of	O
5	O
.	O
3	O
and	O
10	O
.	O
6	O
months	O
,	O
respectively	O
(	O
Minegishi	O
et	O
al	O
.	O
2011	O
).	O

Only	O
one	O
patient	O
(	O
5	O
.	O
6	O
%)	O
with	O
IPF	B-DS
developed	O
an	O
AE	O
(	O
after	O
four	O
cycles	O
of	O
chemotherapy	O
).	O

However	O
,	O
in	O
another	O
study	O
4	O
/	O
15	O
patients	O
with	O
NSCLC	B-DS
and	O
ILD	B-DS
who	O
received	O
carboplatin	O
and	O
paclitaxel	O
developed	O
grade	O
3	O
or	O
higher	O
pneumonitis	B-DS
(	O
27	O
%)	O
(	O
Shukuya	O
et	O
al	O
.	O
2010	O
);	O
this	O
high	O
incidence	O
cannot	O
be	O
ignored	O
.	O

In	O
a	O
phase	O
III	O
trial	O
,	O
administration	O
of	O
albumin	B-GP
-	O
bound	O
paclitaxel	O
(	O
nab	O
-	O
paclitaxel	O
)	O
as	O
first	O
-	O
line	O
treatment	O
in	O
patients	O
with	O
advanced	O
NSCLC	B-DS
without	O
ILD	B-DS
was	O
effective	O
and	O
resulted	O
in	O
a	O
higher	O
RR	O
than	O
conventional	O
solvent	O
-	O
based	O
paclitaxel	O
(	O
Socinski	O
et	O
al	O
.	O
2012	O
).	O

Currently	O
,	O
several	O
clinical	O
trials	O
are	O
assessing	O
a	O
combination	O
of	O
carboplatin	O
and	O
nab	O
-	O
paclitaxel	O
for	O
advanced	O
NSCLC	B-DS
with	O
ILD	B-DS
.	O

Nintedanib	O
is	O
a	O
multiple	O
tyrosine	B-GP
kinase	I-GP
inhibitor	O
,	O
and	O
INPULSIS	O
-	O
2	O
trial	O
demonstrated	O
that	O
nintedanib	O
reduced	O
the	O
time	O
to	O
first	O
AE	O
compared	O
with	O
placebo	O
(	O
Richeldi	O
et	O
al	O
.	O
2014	O
).	O

In	O
addition	O
,	O
a	O
combination	O
of	O
docetaxel	O
and	O
nintedanib	O
showed	O
a	O
benefit	O
on	O
OS	O
over	O
docetaxel	O
monotherapy	O
as	O
second	O
-	O
line	O
treatment	O
(	O
Reck	O
et	O
al	O
.	O
2014	O
).	O

The	O
addition	O
of	O
nintedanib	O
to	O
cytotoxic	O
agents	O
such	O
as	O
docetaxel	O
may	O
be	O
more	O
effective	O
with	O
fewer	O
adverse	O
events	O
.	O

The	O
prevalence	O
of	O
ILD	B-DS
and	O
IPF	B-DS
in	O
this	O
study	O
was	O
24	O
.	O
3	O
and	O
15	O
.	O
6	O
%,	O
respectively	O
,	O
and	O
seems	O
to	O
be	O
higher	O
than	O
in	O
previous	O
reports	O
(	O
7	O
.	O
3	O
–	O
14	O
%)	O
(	O
Kinoshita	O
et	O
al	O
.	O
2012	O
;	O
Nishino	O
et	O
al	O
.	O
2015	O
).	O

However	O
,	O
among	O
387	O
patients	O
who	O
received	O
surgical	O
resection	O
,	O
65	O
(	O
16	O
.	O
8	O
%)	O
were	O
confirmed	O
as	O
underlying	O
IPF	B-DS
(	O
Goto	O
et	O
al	O
.	O
2014	O
).	O

Location	O
of	O
the	O
institution	O
would	O
greatly	O
influence	O
the	O
prevalence	O
of	O
ILD	B-DS
and	O
IPF	B-DS
as	O
well	O
as	O
smoking	O
status	O
.	O

The	O
limitations	O
of	O
this	O
study	O
are	O
as	O
follows	O
.	O

First	O
,	O
this	O
was	O
a	O
retrospective	O
,	O
single	O
-	O
center	O
study	O
;	O
a	O
prospective	O
,	O
multicenter	O
large	O
study	O
including	O
both	O
non	O
-	O
ILD	B-DS
and	O
ILD	B-DS
patients	O
is	O
desirable	O
to	O
further	O
investigate	O
clinical	O
differences	O
in	O
response	O
to	O
chemotherapy	O
.	O

Second	O
,	O
all	O
patients	O
were	O
Japanese	O
:	O
Some	O
studies	O
have	O
shown	O
ethnic	O
differences	O
in	O
incidence	O
of	O
drug	O
-	O
induced	O
lung	O
injury	O
and	O
other	O
pulmonary	B-DS
diseases	I-DS
(	O
Azuma	O
et	O
al	O
.	O
2008	O
;	O
Natsuizaka	O
et	O
al	O
.	O
2014	O
).	O

The	O
incidence	O
of	O
AEs	O
of	O
ILD	B-DS
/	O
IPF	B-DS
may	O
vary	O
between	O
different	O
ethnicities	O
.	O

Conclusions	O

This	O
study	O
showed	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
patients	O
with	O
advanced	O
NSCLC	B-DS
and	O
IPF	B-DS
have	O
shorter	O
PFS	O
and	O
OS	O
and	O
lower	O
DCR	O
than	O
patients	O
without	O
ILD	B-DS
.	O

Docetaxel	O
-	O
containing	O
chemotherapeutic	O
regimens	O
were	O
more	O
frequently	O
associated	O
with	O
AEs	O
than	O
other	O
regimens	O
.	O

Because	O
survival	O
after	O
onset	O
of	O
AEs	O
is	O
usually	O
short	O
,	O
more	O
effective	O
therapeutic	O
strategies	O
that	O
do	O
not	O
induce	O
AEs	O
should	O
be	O
identified	O
.	O

